Citations

Clear

11 citation(s) found for "Santiago, Jose".

Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treat Pseudomonas aeruginosa clinical isolates
Mystakelis, Harry, Shields, Ryan K. , Bergman, Yehudit , Munita, José M. , Cosgrove, Sara E. , Simner, Patricia J. , Tamma, Pranita D. , Bergman, Yehudit , Munita, Jose M , Cosgrove, Sara E , Tamma, Pranita D , Mystakelis, Harry , Mathers, Amy J.

Mayo Clinic

JAC-Antimicrobial Resistance | July 16, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/jacamr/dlag138 | PMID 42465584 Get It

Abstract Objectives This study aimed to characterize susceptibility profiles of both currently approved and investigational β-lactam agents against difficult-to-treat resistant Pseudomonas aeruginosa (DTR P. aeruginosa) clinical isolates, including carbapenemase-producing strains. Patients and methods A total of 502 consecutive DTR P. aeruginosa clinical isolates were collected from unique hospitalized patients between 2022 and 2024 across three tertiary care centres. Isolates originated from bloodstream, respiratory, urinary and intra-abdominal infections. Minimum inhibitory concentrations (MICs) for seven β-lactam agents were determined using triplicate reference broth microdilution. Susceptibility interpretations were based on CLSI criteria or, where applicable, investigational breakpoints. Whole-genome sequencing was performed to detect β-lactamase genes. Results Among the 502 isolates, cefepime-zidebactam exhibited the highest in vitro activity (100% susceptibility), followed by cefiderocol-xeruborbactam (98%), cefiderocol (95%), ceftolozane-tazobactam (90%), cefepime-taniborbactam (86%), ceftazidime-avibactam (85%), and imipenem-relebactam (41%). Notably, only 35% of isolates were susceptible to all seven agents. Carbapenemase genes were identified in 4% of isolates, including blaGES (n = 13), blaVIM (n = 7), blaKPC (n = 1) and blaIMP (n = 1). Among carbapenemase-producing isolates, cefepime-zidebactam retained activity against all isolates (100%), exceeding that of other approved β-lactam/β-lactamase inhibitor combinations (0%–24% susceptible), cefiderocol (76%), cefiderocol-xeruborbactam (86%) and cefepime-taniborbactam (81%). Conclusions While currently approved β-lactam agents retained activity against many DTR P. aeruginosa isolates, their performance was markedly compromised in the presence of carbapenemases, with the notable exceptions of cefepime-zidebactam and cefiderocol. Investigational β-lactam/β-lactamase inhibitor combinations exhibited consistently robust activity across resistance phenotypes, including carbapenemase-producing isolates, representing promising options for DTR P. aeruginosa infections.
A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam
Sharara, Sima L. , Diaz, Lorena, Asempa, Tomefa E, Martinez, Jose R W, Canales, Nicolas, Bergman, Yehudit , Murphy, Shannon G. , Karaba, Sara M. , Clark, Andrew E. , Zurawski, Daniel V, Cosgrove, Sara E, Simner, Patricia J, Munita, José M. , Tamma, Pranita D. , Tamma, Pranita D , Clark, Andrew E. , Karaba, Sara M , Bergman, Yehudit , Munita, Jose M , Sharara, Sima L. , Díaz, Lorena , Asempa, Tomefa E. , Canales, Nicolás, Murphy, Shannon G. , Zurawski, Daniel V. , Cosgrove, Sara E. , Simner, Patricia J.

Mayo Clinic

Clinical Infectious Diseases | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/cid/ciag436 | PMID 42442753 Get It

Abstract We report an eightfold increase in sulbactam-durlobactam MICs in a carbapenem-resistant Acinetobacter baumannii cerebrospinal fluid isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas
Gottesdiener, Lee , Li, Yixuan, Greenwood‐Quaintance, Kerryl E. , Komarow, Lauren, Arias, César A. , Cober, Eric, Herc, Erica , Kaye, Keith S., Huskins, W. Charles, Figueroa, Jairo, Vilchez, Samuel, Leroi, Marcel, Rioseco, María L., Munita, Jose M., Reyes, Jinnethe , Kreiswirth, Barry N. , Hill, Carol, Baum, Keri, Chambers, Henry F., Fowler, Vance G. , Doi, Yohei, Satlin, Michael J., Group, on behalf of the Antibacterial Resistance Leadership, Munita, José M. , Fries, Bettina C , Reyes, Jinnethe , Chen, Liang , Kreiswirth, Barry N , Villegas, Maria Virginia , Paterson, David L. , Bonomo, Robert A , Fowler, Vance G. , Patel, Robin , van Duin, David , Satlin, Michael J , Evans, Scott R , Munita, Jose M , Komarow, Lauren , Arias, César A. , Cober, Eric , Kaye, Keith S. , Huskins, W. Charles , Fries, Bettina C. , Leroi, Marcel , McCarty, Todd P , Rioseco, María Luisa, Stryjewski, Martín E. , Hill, Carol , Baum, Keri, Villegas, María Virginia , Bonomo, Robert A. , Chambers, Henry F. , Patel, Robin , Doi, Yohei , Satlin, Michael J.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 15, 2026 | Volume: 70 | Issue: 6 | Pages: No page available

10.1128/aac.00388-25 | PMID 42138639 Get It

ABSTRACT Novel β-lactam/β-lactamase inhibitors (βL/βLIs) are important therapies for carbapenem-resistant Pseudomonas aeruginosa (CRPA). However, the global extent of resistance to these agents and the impact of resistance on patient outcomes are unclear. We therefore evaluated patients with CRPA isolates at 35 hospitals (nine countries) from December 2018 to November 2019. Antimicrobial susceptibility testing was performed at a central laboratory by agar dilution for ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) and by broth microdilution for imipenem-relebactam (I/R). Characteristics and outcomes, including desirability of outcome rankings (DOOR), were compared between patients infected with isolates not susceptible vs susceptible to each agent. Of 800 CRPA isolates, susceptibility to C/T, CZA, and I/R was 69%, 67%, and 33%, respectively. USA isolates ( n = 526) were more frequently susceptible to these agents than isolates from other countries ( n = 274; C/T: 83% vs 42%; CZA: 77% vs 47%; I/R: 37% vs 23%; P < 0.001 for each comparison) and isolates with carbapenemases ( n = 157) were less frequently susceptible than isolates without carbapenemases ( n = 643; C/T: 7% vs 84%; CZA: 24% vs 77%; I/R: 6% vs 39%; P < 0.001 for each comparison). Thirty-day mortality and DOOR were similar overall in patients infected with isolates not susceptible vs susceptible to each βL/βLI. However, the adjusted probability of a better DOOR outcome for a randomly selected patient with bacteremia due to a C/T-not susceptible vs -susceptible isolate was 38.2% (95% confidence interval, 25.6%–52.7%). Resistance to novel βL/βLIs, especially I/R, is common in CRPA, particularly outside the USA and in carbapenemase-producing isolates. Additional treatment options are needed for CRPA infections.
Family History and Solar Insolation in Bipolar I Disorder
Bauer, M., Glenn, Tasha , Achtyes, E. D., Alda, M., Ağaoğlu, Esen , Altınbaş, Kürşat , Andreassen, O. A., Angelopoulos, E., Ardau, R., Aydin, Mehmet Zeki , Ayhan, Y., Baethge, Christopher , Bauer, Rita, Baune, B. T., Balaban, Ceylan, Becerra‐Palars, Claudia, Behere, A. P., Belete, Habte , Belete, Tilahun, Belizario, G. Okawa, Bellivier, F., Belmaker, R. H., Benedetti, F., Berk, M., Bersudsky, Y., Bicakci, Ş., Birabwa‐Oketcho, Harriet , Bjella, T. D., Brady, Conan , Cabrera, Jorge , Cappucciati, Marco , Castro, A. M. Paredes, Chen, W., Cheung, E. Y. W., Chiesa, S., Chanopoulou, Margarita, Cuomo, A., Dodd, S., Etain, B., Fagiolini, A., Fellendorf, F. T., Ferensztajn‐Rochowiak, Ewa , Fiedorowicz, J. G., Fountoulakis, K. N., Frye, M. A., Geoffroy, P. A., Gitlin, M. J., Gottlieb, J. F., Grof, Paul , Haarman, B.C.M., Harima, Hirohiko, Hasse‐Sousa, M., Henry, C., Hoffding, L., Houenou, J., Imbesi, M., Isometsä, E. T., Janno, Sven , Johnsen, S., Karakatsoulis, G. N., Kardell, Mathias, Kessing, L. V., Kim, S. J., Kot, T. L., Koval, M., Lafer, B., Landén, M., Larsen, E. R., Licht, R. W., Ludwig, V. M., Mackenzie, Alan, Madsen, H. Østergaard, Madsen, S. Alberte Kongstad A., Mahadevan, J., Mahardika, Agustine , Mahfoudh, K. Ben, Manchia, M., Marsh, W., Martiny, Klaus , Mashima, Y., McLoughlin, D. M., Meesters, A. N. R., Meesters, Ybe , Melle, I., Meza‐Urzúa, F., Michaelis, Elisabeth, Mok, Y. Ming, Monteith, Scott , Moorthy, Muthukumaran, Morken, G., Mosca, Enrica, Mozzhegorov, A. A., Munoz, R., Mythri, S. V., Nadella, R. K., Nakanotani, Takako, Nielsen, R. Ernst, O'Donovan, C., Omrani, Adel, Osher, Yamima , Pantovic‐Stefanovic, M., Pariwatcharakul, Pornjira, Petite, Joanne, Pilhatsch, M., Ruiz, Y. Pica, Pinna, M., Pompili, M., Porter, R., Quiroz, Danilo , Rabelo‐da‐Ponte, F. Diego, Ramesar, Raj , Rasgon, NL, Redahan, Maria, Reddy, M. S., Reif, A., Reininghaus, E. Z., Richards, J. Gringer, Rybakowski, J. K., Sathyaputri, Leela, Scippa, A. M., Simhandl, Christian , Smith, D., Smith, J., Stackhouse, P. W., Stein, D. J., Stilwell, Kellen, Su, K.‐P., Sulaiman, A. Hatim, Suominen, Kirsi, Tanra, A. J., Tatebayashi, Yoshitaka , Teh, W. Lin, Tondo, L., Torrent, C., Tuinstra, Daniel, Uchida, Takahito, Vaaler, A. E., Vieta, E., Viswanath, B., Volf, C., Yang, K‐J, Yalcinkaya, O. Kaan, Young, A. H., Zgueb, Yosra , Whybrow, P. C., Houenou, Josselin , Isometsä, Erkki , Licht, Rasmus Wentzer , Manchia, Mirko , Nielsen, René Ernst , Stein, Dan J. , Kessing, Lars Vedel , Young, Allan H. , Achtyes, Eric D. , Belete, T , Berk, Michael , Crowe, M , Fagiolini, Andrea , Frye, Mark , Grof, P , Kessing, L V , Kim, S J , Manchia, Mirko , McLoughlin, D M , Nadella, R K , Ouali, U , Pariwatcharakul, P , Pompili, M , Porter, R , Ritter, P , Rybakowski, Janusz K , Stein, Dan J , Strejilevich, S , Subramaniam, M , Vaaler, A E , Vieta, E , Yoldi-Negrete, M , Young, Allan H , Bauer, M., Alda, Martin , Altınbaş, Kürşat , Andreassen, Ole A. , Angelopoulos, Elias, Ardau, Raffaella , Aydin, M., Ayhan, Yavuz , Behere, Aniruddh Prakash, Belizário, Gabriel Okawa , Bellivier, Frank , Belmaker, Robert H. , Benedetti, Francesco , Berk, Michael , Bıçakcı, Şule , Bjella, Thomas , Castro, Angela Marianne Paredes , Cuomo, Alessandro, Dallaspezia, Sara , Desai, Pratikkumar Vrajeshbhai , Dodd, Seetal , Étain, Bruno , Fagiolini, Andrea , Fellendorf, F.T., Fiedorowicz, Jess G. , Fountoulakis, Konstantinos Ν. , Frye, Mark A. , Geoffroy, Pierre A. , Gitlin, Michael , González‐Pinto, Ana , Haarman, Bartholomeus C. M. , Hasse-Sousa, Mathias , Henry, Chantal , Høffding, Lone, Imbesi, Massimiliano, Ivković, Maja , Johnsen, Søren Paaske , Kapczinski, Flávio , Karakatsoulis, Grigorios N. , König, Barbara , Kunz, Maurício , Lafer, Beny , Landén, Mikael , Ludwig, Vera Miriam , López‐Jaramillo, Carlos , MacKenzie, A., Madsen, Helle Østergaard , Mahfoudh, K., Marsh, W., Martínez‐Cengotitabengoa, Mónica , Martini, Julia , Mashima, Yuki , Meesters, Alie N.R., Melle, Ingrid , Meza-Urzúa, Fátima, Mikoláš, Pavol , Mok, Yee Ming , Morken, Gunnar , Mozzhegorov, Anton A., Mythri, SV, C, O'Donovan, Ouali, Uta , Stefanovic, M. Pantovic, Pfennig, Andrea , Ruiz, Yolanda Pica, Pinna, Marco , Rabelo-Da-Ponte, F.D., Rasgon, Natalie , Ratta‐apha, Woraphat , Redahan, Maria, Reif, A., Reininghaus, EZ, Ritter, Philipp , Strejilevich, Sergio , Suominen, Kirsi, Teh, Wen Lin , Torrent, C., Vieta, Eduard , Viswanath, Biju , Yoldi‐Negrete, María , Young, A.H., Whybrow, Peter C.

Mayo Clinic

Acta Psychiatrica Scandinavica | March 8, 2026 | Volume: 153 | Issue: 4 | Pages: 270-278

10.1111/acps.70075 | PMID 41734899 Get It

ABSTRACT Background Sunlight has profound impacts on physical and mental health, beyond vision, including effects on circadian rhythms, alertness, mood, and sleep. A family history of any mood disorders is strongly associated with psychiatric disorders including bipolar disorder. The purpose of this study was to evaluate the association between a family history of any mood disorder in patients with bipolar I disorder and solar insolation at varied international onset locations. Methods Data for this analysis were available from 5842 patients with a diagnosis of bipolar I disorder obtained at 83 collection sites in both hemispheres. This included 4752 patients from 71 collection sites in the northern hemisphere and 1090 patients from 12 collection sites in the southern hemisphere. Patient data variables were obtained from records or interviews. Solar insolation data were obtained from The National Aeronautics and Space Administration (NASA) Power database for each onset location, and the ratio of the mean monthly minimum/mean monthly maximum solar insolation was calculated. Typically, the ratio is largest near the equator (little yearly change in solar insolation) and smallest near the poles (large yearly change in solar insolation). Results A significant relationship was found between a family history of any mood disorder, the ratio of the mean monthly minimum/mean monthly maximum solar insolation, and gender. The odds of a family history of mood disorder increased as patient location nears the poles and decreased near the equator. Female gender also increased the odds of having a family history of a mood disorder. Conclusions This study highlighted the association between family history, solar insolation, and gender in international patients with bipolar I disorder. Given the profound effects of sunlight on human health, the family of patients with bipolar disorder who live in the same location with the same solar insolation, and especially females, may be at increased risk for a mood disorder.
Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections
Boutzoukas, Angelique E , Mackow, Natalie , Giri, Abhigya, Komarow, Lauren , Hill, Carol , Chen, Liang , Doi, Yohei , Satlin, Michael J. , Arias, César A. , Wang, Minggui , Moreo, Laura Mora , Herc, Erica , Cober, Eric , Weston, Gregory , Fowler, Vance G. , Pettigrew, Melinda M. , Jabbour, Jean-Francois , Reyes, Jinnethe , Munita, José M. , Valderrama, Sandra , Patel, Robin , van Duin, David , Chen, Liang , Doi, Yohei , Pettigrew, M M , Evans, Scott R , Wang, Minggui , Reyes, Jinnethe , Munita, Jose M , Arias, César A. , Weston, Gregory , Patel, Robin , Bonomo, Robert A. , Fowler, Vance G.

Mayo Clinic

Journal of Antimicrobial Chemotherapy | September 5, 2024 | Volume: 79 | Issue: 11 | Pages: 2916-2922

10.1093/jac/dkae306 | PMID 39236214 Get It

Abstract Background The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI). Methods Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI. Results Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P &lt; 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P &lt; 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%–64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P &lt; 0.001]. Conclusion We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.
Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry
Garweg, Christophe , Clementy, Nicolas, Al-Samadi, Faisal, Iacopino, Saverio , Roberts, Paul R. , Johansen, Jens Brock , Vinolas-Prat, X., Cha, Yong‐Mei , Grubman, Eric , Bordachar, Pierre , Fagan, Dedra H. , Piccini, Jonathan P. , El-Chami, Mikhael F , Garweg, Christophe , Johansen, Jens Brock , Cha, Yong-Mei , Stromberg, Kurt , El‐Chami, Mikhael F. , Clémenty, Nicolas , Martínez‐Sande, José Luis , Tondo, Claudio , Stromberg, Kurt

Mayo Clinic

European Heart Journal | February 9, 2024 | Volume: 45 | Issue: 14 | Pages: 1241-1251

10.1093/eurheartj/ehae101 | PMID 38426911 Get It

Abstract Background and Aims Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed. Methods All Micra PAR patients undergoing implant attempts were included. Endpoints included system- or procedure-related major complications and system revision rate for any cause through 60 months post-implant. Rates were compared through 36 months post-implant to a reference dataset of 2667 transvenous pacemaker patients using Fine–Gray competing risk models. Results 1809 patients were enrolled between July 2015 and March 2018 and underwent implant attempts from 179 centres in 23 countries with a median follow-up period of 51.1 months (IQR: 21.6–64.2). The major complication rate at 60 months was 4.5% [95% confidence interval (CI): 3.6%–5.5%] and was 4.1% at 36 months, which was significantly lower than the 8.5% rate observed for transvenous systems (HR: .47, 95% CI: .36–.61; P &lt; .001). The all-cause system revision rate at 60 months was 4.9% (95% CI: 3.9%–6.1%). System revisions among Micra patients were mostly for device upgrades (41.2%) or elevated thresholds (30.6%). There were no Micra removals due to infection noted over the duration of follow-up. At 36 months, the system revision rate was significantly lower with Micra vs. transvenous systems (3.2% vs. 6.6%, P &lt; .001). Conclusions Long-term outcomes with the Micra leadless pacemaker continue to demonstrate low rates of major complications and system revisions and an extremely low incidence of infection.
Genome-wide association meta-analysis of 5,864 individuals highlights 25 new loci implicated in the pathogenesis of cancer therapy-related cardiac dysfunction
Campelo, Laura Martínez, Verea, Alejandro Blanco, Fernandez, T Lopez, Monzonís, A. Martínez, Buno, A, Mazón, Pilar, Sendón, José Luis López, Fernandez, T Lopez, Buno, A, Norton, Nadine , Velasco, A, Carracedo, Ángel , González‐Juanatey, José Ramón , Brión, Marı́a

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.3057 Get It

Abstract Background Cancer therapy-related cardiac dysfunction, which commonly includes varying degrees of asymptomatic ventricular dysfunction and/or heart failure, is the main adverse effect of anticancer therapy. The mechanism by which it develops is still quite uncertain. In recent years several genetic association studies have identified common genetic variants associated with cardiotoxicity in genes related to DNA damage, drug transportation and metabolism, antioxidant mechanism, sarcomere dysfunction and impaired iron metabolism, but the evidence is still limited. Rare variants in familial cardiomyopathies genes have also been identified. Purpose This uncertainly requires larger studies to identify genetic variants allowing to predict the risk of cardiotoxicity. In this sense, we carry out a genome-wide association meta-analysis to identify genetic variants associated with cancer therapy-related cardiac dysfunction. The development of a risk predictor model combining clinical and genetic factors would make it possible to anticipate the adverse effects of this therapy. Methods Genome wide meta-analysis was performed with a total of 594 patients from the CARDIOTOX registry and 3545 healthy individuals from the National DNA Bank, together with three previously published independent cohorts with 1446, 227 and 52 individuals receiving cancer therapy. Patients were classified with different cardiotoxicity degrees based on the CARDIOTOX registry and exhaustive clinical information was obtained from medical records. The study was ethically approved by local institutional review boards and all participants provided written informed consent. DNA samples were genotyped and imputed to perform a GWAS meta-analysis for case-control (n=5864) and extreme phenotypes (n=5317) looking for genetic variants that predispose to developing cancer therapy-related cardiac dysfunction. A functional characterization of the significant loci was performed by colocalization with eQTLs. Results The case-control analysis showed 17 loci that achieved suggestive significance (&lt; P=1 x10-5) (Figure 1). The rs6765460, an intergenic variant between TPRG1 and TP63 genes, had the strongest relationship with the development of cardiotoxicity (P=1.89x10-7). The extreme phenotypes analysis showed additional 8 loci that achieved suggestive significance. The rs12904266, an intron variant of SLCO3A1, had the strongest relationship with severe cardiotoxicity (P=3.20E-07). eQTLs colocalization of the significant loci revealed association with genes involved in the mitochondria, inflammation, immune system, and fibrosis. Conclusions Our GWAS meta-analysis identified 25 novel genetic variants that may be associated with cancer therapy-related cardiac dysfunction. Genotyping of these markers could be considered in a genetic risk score which, together with the already known clinical risk factors, would improve the cardiotoxicity prediction in cardio-oncology units.Figure 1.Miami plot with P values
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions
Wang, Minggui , Ge, Lizhao , Chen, Liang , Komarow, Lauren , Hanson, Blake , Cober, Eric , Alenazi, Thamer H. , Xie, Qing , Liu, Zhengyin , Li, Lanjuan , Yu, Yunsong , Gao, Hainv , Figueroa, Jairo, Herc, Erica , Córdova, Ezequiel , Weston, Gregory , Kaye, Keith S. , Dhar, Sorabh , Munita, José M. , Salata, Robert A. , Vilchez, Samuel, Stryjewski, Martín E. , Iovleva, Alina , Evans, Scott , Baum, Keri, Hill, Carol , Kreiswirth, Barry N. , Patel, Robin , Arias, Cesar A, Chambers, Henry F. , Fowler, Vance G. , Satlin, Michael J. , Investigators, Multi-Drug Resistant Organism Network, Zhang, Fujie , Castelnuovo, Valentina Di, Gutierrez, Jose Millan Oñate, Evans, Beth , Cross, H. R. , Arias, Rebekka M. , Fowler, Vance G, Ordóñez, Karen , Li, Linghua , Kreiswirth, Barry N , Desai, Samit, Rioseco, María Luisa, Vilchez, Samuel, Sánchez, Marisa , Valderrama, Sandra , Figueroa, Jairo, Arias, Cesar A, Dinh, An Q , Panesso, Diane, Rydell, Kirsten, Tran, Truc T. , Jiang, Jianping , Xu, Xiaogang , Spencer, María, Marshall, Steven H. , Rudin, Susan D., Greenwood-Quaintance, Kerry, Schmidt-Malan, Suzannah M., Revolinski, Sara , Wortmann, Glenn , Kalayjian, Robert C. , Ostrowsky, Belinda , Patel, Gopi , Eiras, Daniel , Garcia-Diaz, Julia, Farrell, John J. , Paterson, David L, Kaye, Keith S, Waters, Mary Jo, Eilertson, Brandon , Ng, Oon Tek , De, Partha Pratim, Chew, Kean Lee , Smitasin, Nares , Gallagher, Jason C , Leroi, Marcel , McCarty, Todd P , Lautenbach, Ebbing , Hanson, Blake, Perez, Federico, Banerjee, Ritu , Dhar, Sorabh, Westblade, Lars F. , Yu, Yunsong , Cordova, Ezequiel , Kaye, Keith S , Evans, Scott R , Patel, Robin , van Duin, David , Pérez, Federico , Jiang, Jianping , Chen, Liang , Wang, Minggui , Munita, Jose M , Reyes, Jinnethe , Zong, Zhiyong , Kanj, Souha S. , Tambyah, Paul Anantharajah , Garcia‐Diaz, Julia , Villegas, María Virginia , Kreiswirth, Barry N , Paterson, David L. , Arias, Cesar A, Bonomo, Robert A. , Fowler, Vance G. , Doi, Yohei , Investigators, Multi-Drug Resistant Organism Network, Lok, Judith J. , Richter, Susan, Anderson, Deverick J. , Evans, Beth, Cross, Heather R, Fowler, Vance G, Jacob, Jesse T. , Manca, Claudia , Vilchez, Samuel, Figueroa, Jairo, Arias, Cesar A, Hu, Fupin , Su, Jiachun , Wang, Minggui, Xu, Xiaogang, Yang, Yang, Huskins, W. Charles , Greenwood‐Quaintance, Kerryl E. , Kim, Angela , Garcia-Diaz, Julia, Salcedo, Soraya , Henderson, Andrew , Paterson, David L, Kaye, Keith S, Fries, Bettina C. , Marimuthu, Kalisvar , Peleg, Anton Yariv , Xiao, Yonghong , Garner, Omai B. , Abbo, Lilian M. , Han, Jennifer , Wong, Darren , Hanson, Blake, Díaz, Lorena

Mayo Clinic

Clinical Infectious Diseases | September 22, 2023 | Volume: 78 | Issue: 2 | Pages: 248-258

10.1093/cid/ciad556 | PMID 37738153 Get It

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb. Methods In a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled at 46 hospitals in five global regions between 2017 and 2019. The primary outcome was all-cause mortality at 30 days from the index culture. The strains underwent whole-genome analysis. Results Of 842 cases, 536 (64%) represented infection. By 30 days, 128 (24%) of the infected patients died, ranging from 1 (6%) of 18 in Australia-Singapore to 54 (25%) of 216 in the United States and 24 (49%) of 49 in South-Central America, whereas 42 (14%) of non-infected patients died. Bacteremia was associated with a higher risk of death compared with other types of infection (40 [42%] of 96 vs 88 [20%] of 440). In a multivariable logistic regression analysis, bloodstream infection and higher age-adjusted Charlson comorbidity index were independently associated with 30-day mortality. Clonal group 2 (CG2) strains predominated except in South-Central America, ranging from 216 (59%) of 369 in the United States to 282 (97%) of 291 in China. Acquired carbapenemase genes were carried by 769 (91%) of the 842 isolates. CG2 strains were significantly associated with higher levels of meropenem resistance, yet non-CG2 cases were over-represented among the deaths compared with CG2 cases. Conclusions CRAb infection types and clinical outcomes differed significantly across regions. Although CG2 strains remained predominant, non-CG2 strains were associated with higher mortality. Clinical Trials Registration. NCT03646227.
Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study
Sami, Sarmed S. , Ravindran, Adharsh, Snyder, Diana L. , Santiago, José , Ortiz‐Fernández‐Sordo, Jacobo , Tan, Wei Keith , Dierkhising, Ross , Johnson, Michele L., Lansing, Ramona, Ragunath, Krish , Pietro, Massimiliano di , Wolfsen, Herbert C. , Ramirez, Francisco C. , Fleischer, David E., Wang, Kenneth K, Leggett, Cadman L. , Katzka, David A. , Iyer, Prasad G. , Kahn, Allon , Snyder, Diana, Dierkhising, Ross A, Crook, Julia E. , Wolfsen, Herbert, Ramirez, Francisco, Fleischer, David, Katzka, D A , Iyer, P G , Leggett, Cadman L , Santiago, Jose, Heckman, Michael G.

Mayo Clinic

Gut | January 11, 2019 | Volume: 68 | Issue: 8 | Pages: 1379-1385

10.1136/gutjnl-2018-317513 | PMID 30635408 Get It

Objective Surveillance interval protocols after complete remission of intestinal metaplasia (CRIM) post radiofrequency ablation (RFA) in Barrett’s oesophagus (BE) are currently empiric and not based on substantial evidence. We aimed to assess the timeline, location and patterns of recurrence following CRIM to inform these guidelines. Design Data on patients undergoing RFA for BE were obtained from prospectively maintained databases of five (three USA and two UK) tertiary referral centres. RFA was performed until CRIM was confirmed on two consecutive endoscopies. Results 594 patients achieved CRIM as of 1 May 2017. 151 subjects developed recurrent BE over a median (IQR) follow-up of 2.8 (1.4–4.4) years. There was 19% cumulative recurrence risk of any BE within 2 years and an additional 49% risk over the next 8.6 years. There was no evidence of a clinically meaningful change in the recurrence hazard rate of any BE, dysplastic BE or high-grade dysplasia/cancer over the duration of follow-up, with an estimated 2% (95% CI −7% to 12%) change in recurrence rate of any BE in a doubling of follow-up time. 74% of BE recurrences developed at the gastro-oesophageal junction (GOJ) (24.1% were dysplastic) and 26% in the tubular oesophagus. The yield of random biopsies from the tubular oesophagus, in the absence of visible lesions, was 1% (BE) and 0.2% (dysplasia). Conclusions BE recurrence risk following CRIM remained constant over time, suggesting that lengthening of follow-up intervals, at least in the first 5 years after CRIM, may not be advisable. Sampling the GOJ is critical to detecting recurrence. The requirement for random biopsies of the neosquamous epithelium in the absence of visible lesions may need to be re-evaluated.